

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Tod R. SMEAL, et al.

Title: GEF-H1b: BIOMARKERS, COMPLEXES, ASSAYS AND
THERAPEUTIC USES THEREOF

Appl. No.: 10/611,671

Filing Date: 7/2/2003

Examiner: XIE, Xiaozhen

Art Unit: 1646

Confirmation Number:
5378

INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR §1.56

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of a document known to
Applicants in order to comply with Applicants' duty of disclosure pursuant to 37 CFR §1.56.

A copy of the non-patent document is being submitted to comply with the provisions
of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not
intended as an admission that such document constitutes prior art against the claims of the
present application or that such document is considered material to patentability as defined in
37 CFR §1.56(b). Applicants do not waive any rights to take any action which would be
appropriate to antedate or otherwise remove as a competent reference any document which is
determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed document is being submitted in compliance with 37 CFR §1.97(c), before the mailing date of either a final action under 37 CFR §1.113, a notice of allowance under 37 CFR §1.311, or an action that otherwise closes prosecution in the application.

RELEVANCE OF EACH DOCUMENT

The listed document was cited as being relevant during the prosecution of the related European patent application, 03763085.2. An English translation of the foreign-language document is not readily available. However, the absence of such translation does not relieve the PTO from its duty to consider the submitted foreign language document (37 CFR §1.98 and MPEP §609).

Applicants respectfully request that the listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

FEE

Fees in the amount of \$180.00 in accordance with 37 CFR §1.17(p) to cover the fee associated with an information disclosure statement under 37 CFR §1.97(c) are being paid by credit card via EFS-Web.


The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 19-0741. Should no proper payment be enclosed herewith, as by the credit card payment instructions in EFS-Web being incorrect or absent, resulting in a rejected or incorrect credit card transaction, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 19-0741.

Respectfully submitted,

Date

11/26/07

By



FOLEY & LARDNER LLP
Customer Number: 22428
Telephone: (202) 672-5475
Facsimile: (202) 672-5399

Beth A. Burrous
Attorney for Applicant
Registration No. 35,087